Pilot Study: CGM-Augmented Food Is Medicine for Type 2 Diabetes

This study is looking at how a "Food Is Medicine" (FIM) program, which provides healthy food vouchers, can help adults with type 2 diabetes. We want to see if adding a continuous glucose monitor (CGM) – a device that tracks blood sugar levels in real-time – and nutrition counseling makes the FIM program more effective. You could be eligible if you are an adult (18 or older) with type 2 diabetes and can complete study activities in English. The study will compare two groups: one receiving FIM with CGM and counseling, and another receiving FIM alone. Success will be measured by changes in your blood sugar levels, specifically how much time your blood sugar is in, below, or above the target range. The current recruitment status is unclear, and we plan to enroll 60 participants.

Study design
This is an interventional study that will randomize 60 participants into two groups for 16 weeks. One group will receive CGM-Augmented FIM, and the other will receive FIM only.
What's involved
You will wear a blinded CGM at the beginning and at week 12, and complete two 24-hour dietary recalls during each wear-time. If in the intervention arm, you will wear a real-time CGM for 12 weeks and have 5-8 nutrition counseling sessions. You will also provide outcome data at 12 and 16 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will provide outcome data at 12 weeks (post-intervention) and 16 weeks (after a 4-week extension phase).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07148713

Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine

Active, Not Recruiting
NAAges 18+InterventionalTreatment
University of North Carolina, Chapel Hill
~60 participants
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:CGM-Augmented FIMFIM only

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in percent of Time in Range (TIR)
Measured over Baseline at Week 0, Post-intervention at Week 12
+7 more outcomes measured
Nutrition
Type 2 Diabetes
T2DM
T2DM (Type 2 Diabetes Mellitus)
Diabetes Education
Diabetes Type 2
Diabetes Mellitis
1 sites across 1 states
North Carolina1
  • Anna Kahkoska, MD, PhD · PRINCIPAL_INVESTIGATOR · University of North Carolina, Chapel Hill

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able to complete study activities in English
Aged ≥18 years
Type 2 diabetes as defined by self-report and confirmed by ICD-10 codes
Chart review will be conducted by the study team and a diagnosis of type 2 diabetes (E.11.xx) from either the problem list or a diagnosis linked to an encounter will be used as confirmation. Discrepancies in diagnosis codes will be resolved by review of provider notes within the past 3 years.
HbA1c \> 8.0% in the last 12 months via point of care or venous measurement. If there are multiple values, the most recent one will be considered.
Receiving primary or specialty care within UNC Health as defined by at least one visit with a primary care provider or endocrine provider within the past year
Indication of a barrier to healthy eating consisting of report of food insecurity (defined as a score greater or equal to 1.0 on the 6-item USDA Food Security Survey Module (FSSM)) and/OR nutrition insecurity (defined as more often than 'Rarely' on the One-Item Gretchen Swanson Nutrition Screener, OR more often than 'Not Very Hard' on the Two-item Nutrition Security Screener (NSS))
Any positive screen on the FSSM, Gretchen Swanson Nutrition Screener, or NSS
No plans to move from the area for at least 4 months
Willing and able to provide written informed consent and participate in all study activities

Exclusion

Type 1 or other diabetes
Use of insulin or secretagogues in the preceding 6 months
Use of CGM in the preceding 6 months
Inability to use CGM and related technology (e.g., the companion app), including lack of a smartphone that is compatible with Stelo (information on compatible phones available in Appendix 1) or known allergy to adhesive
Known psychosis or major psychiatric illness that prevents participation with study activities
Pregnancy or planned pregnancy in the next 4 months-glycemic targets are different for pregnant women compared to non-pregnant women with diabetes and our intervention is designed for non-pregnant glycemic targets
Participant in diabetes, nutrition, or weight research intervention in last 12 months
  • Change in percent of Time in Range (TIR)Baseline at Week 0, Post-intervention at Week 12

    When using the blinded continuous glucose monitors (CGM), the percentage of sensor values between 70-180 mg/dL will be measured using 7-14 days of retrospective data at each time-point. Change in TIR will be calculated across time-points.

  • Change in percent of Time Below Range (TBR)Baseline at Week 0, Post-intervention at Week 12

    When using the blinded continuous glucose monitors (CGM), the percentage of sensor values in the hypoglycemic range (\<70 mg/dL) will be measured using 7-14 days of retrospective data at each time-point. Change in TBR will be calculated across time-points.

  • Change in percent of Time Above Range (TAR)Baseline at Week 0, Post-intervention at Week 12

    When using the blinded continuous glucose monitors (CGM), the percentage of sensor values in the hyperglycemia range (\>180 mg/dL) will be measured using 7-14 days of retrospective data at each time-point. Change in TAR will be calculated across time-points.

  • Glycemic variabilityBaseline at Week 0, Post-intervention at Week 12

    When using the blinded continuous glucose monitors (CGM), glycemic variability will be assessed using the coefficient of variation (%CV). Change in %CV will be calculated across time-points.

  • Change in Hemoglobin A1c (HbA1c)Baseline at Week 0, Post-intervention at Week 12

    HbA1c (%) reflects average glucose over the past 2-3 months. Value will be assessed by standardized laboratory assay for trial baseline and endpoint.

  • Change in Healthy Eating Index (HEI) Score based on two 24-hour recallsBaseline at Week 0, Post-intervention at Week 12, Post-extension at Week 16

    Participants will be contacted to collect two 24-hour dietary recalls per timepoint. Healthy Eating Index (HEI) scores will be calculated based on the recall responses using a scoring system providing cumulative points for participants eating from a select list of healthy food categories. The scores range from 0 to 100. An ideal overall Healthy Eating Index score of 100 reflects that the set of foods aligns with key dietary recommendations from the Dietary Guidelines for Americans (DGA).

  • Change in Mediterranean diet scoresBaseline at Week 0, Post-Intervention at Week 12, Post-extension at Week 16

    Participants will be contacted to collect two 24-hour dietary recalls per timepoint. Mediterranean diet scores will be calculated based on the recall responses using a scoring system providing cumulative points for participants eating a set amount of serving from a select list of healthy food categories. The scores range from 0 to 9. An ideal overall Mediterranean diet score of 9 reflects that the set of foods aligns with key dietary recommendations from the Dietary Guidelines for Americans (DGA).

  • Change in Dietary Approaches to Stop Hypertension (DASH) ScoresBaseline at Week 0, Post-Intervention at Week 12, Post-extension at Week 16

    Participants will be contacted to collect two 24-hour dietary recalls per timepoint. Dietary Approaches to Stop Hypertension (DASH) scores will be calculated based on the recall responses using a scoring system providing cumulative points for participants eating a set amount of serving from a select list of healthy food categories. The scores range from 8 to 40. An ideal overall DASH score of 40 reflects that the set of foods aligns with key dietary recommendations from the Dietary Guidelines for Americans (DGA).